Company: AZN
Filing Date: 2025-09-17
Form Type: 6-K
Source: 0001654954-25-010845
Chunk: 4

Company: ASTRAZENECA PLC
Filing Date: 2025-09-17
Form: 6-K
Chunk 4
---
, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022;6(10):447-456

9. Kim G-D, et al. Macrophage Polarization and Functions in Pathogenesis of Chronic Obstructive Pulmonary Disease. Int J Mol Sci. 2024;25(11):5632.

10. Vogelmeier CF, AstraZeneca H1 and Q2 Results. Available at: https://www.astrazeneca.com/media-centre/press-releases/2025/h1-and-q2-2025.html . [Last accessed: September 2025]Goals of COPD treatment: Focus on symptoms and exacerbations. Respir Med . 2020;166:105938.

11. Quaderi SA, Hurst JR. The unmet global burden of COPD. Global Health, Epid and Geno. 2018;3,e4.

12. Alwafi H, et al. Trends in hospital admissions and prescribing due to chronic obstructive pulmonary disease and asthma in England and Wales between 1999 and 2020: an ecological study. BMC Pulm Med . 2023;34(2):49.

13. WHO Fact Sheet. The Top 10 Causes of Death. Available at: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death . [Last accessed: September 2025].

14. Clinicaltrial.gov. Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations (RESOLUTE). Available at: https://clinicaltrials.gov/study/NCT04053634. [Last accessed: September 2025].

15. AstraZeneca Data on File. 2025. Fasenra Number of Cumulative Patients. REF-279705.

16. AstraZeneca H1 and Q2 Results 2025. Available at: https://www.astrazeneca.com/media-centre/press-releases/2025/h1-and-q2-2025.html . [Last accessed: September 2025].

#### Matthew Bowden

#### Company Secretary

#### AstraZeneca PLC
[i]The primary endpoint was the annualised rate of moderate or severe chronic obstructive pulmonary